Atai Life Sciences N.V. (ATAI)

$5.47 +0.24 (4.59%)
Market Cap 1.22B
Revenue (ttm) 310,000.00
Net Income (ttm) -149.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -48,151.61%
Debt to Equity Ratio 0.00
Volume 4,532,400
Avg Vol 5,909,588
Day's Range N/A - N/A
Shares Out 233.78M
Stochastic %K 56%
Beta 1.58
Analysts Strong Sell
Price Target $11.17

Company Profile

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 793 2536
Website: atai.com
Address:
Prof. J.H. Bavincklaan 7, Amstelveen, Netherlands
DriuxP
DriuxP Oct. 7 at 5:10 AM
$ATAI
1 · Reply
woodhous
woodhous Oct. 7 at 4:42 AM
$ATAI uupppp
0 · Reply
twiggs462
twiggs462 Oct. 7 at 3:16 AM
$ATAI "[ATAI] 20-30B Company in the next years" - Christian Angermayer
0 · Reply
sirdudeness
sirdudeness Oct. 7 at 2:43 AM
$ATAI Pardon me if someone has already posted this. https://studyfinds.org/single-psilocybin-dose-reverses-pain-depression/
0 · Reply
McGuireTO
McGuireTO Oct. 7 at 1:59 AM
$ATAI $MNMD $CMPS $PSIL Sorry it's been so long since my last update, as explained in this video - Travel in the Caribbean, Stomach flu, and surgery on my nose kept me unable to record an update. But here it is, detailing what we're looking for into tomorrow and the rest of the week!
1 · Reply
Tifosi007
Tifosi007 Oct. 7 at 1:23 AM
$ATAI Cathie’s confidence keeps building
1 · Reply
McGuireTO
McGuireTO Oct. 7 at 1:13 AM
$ATAI $MNMD $CMPS $PSIL Click here to watch the free video! Where do we stand in the psychedelic sector now that ATAI's BPL-009 Phase 3a readout broke out to higher highs, and CMPS and MNMD finally broke through their resistances? Are we anticipating continuation? What about CYBN? I cover it all in this video. I post regular technical analysis of the psychedelic sector, be sure to Like this post and follow me to stay on top of things and not miss an update! https://www.tradingview.com/chart/CYBN/XInp84lQ-Psychedelic-Sector-Update-Oct-6th/
1 · Reply
gemini112
gemini112 Oct. 7 at 12:37 AM
$ATAI Is this first time cathie wood buy this stock?
1 · Reply
UncleRoman09
UncleRoman09 Oct. 6 at 9:23 PM
$ATAI nation! Hedged of a large portion to average up on Datavault (DVLT) highly recommend at least taking a look
0 · Reply
ArsenalFC23
ArsenalFC23 Oct. 6 at 7:21 PM
$ATAI sold my complete position today for a 20% loss. Not too bad considering I was down 80% one year ago. My strategy shift away from pre revenue Bios is now almost complete. Only two I'm still holding are $SLS and $VTGN.
4 · Reply
Latest News on ATAI
Atai Life Sciences: Still A Decent Prospect - But Only Just

Oct 1, 2025, 2:40 PM EDT - 5 days ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 2:50 PM EDT - 13 days ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 23, 2025, 7:00 AM EDT - 13 days ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Sep 9, 2025, 6:59 AM EDT - 27 days ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

atai Life Sciences to Participate in September Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 5 weeks ago

atai Life Sciences to Participate in September Investor Conferences

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 5:01 PM EDT - 2 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 10:58 AM EDT - 2 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 28, 2025, 8:13 AM EDT - 2 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:16 PM EDT - 2 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 25, 2025, 4:05 PM EDT - 2 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 2, 2025, 2:29 PM EDT - 3 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 9:28 AM EDT - 3 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:05 AM EDT - 3 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jul 1, 2025, 6:00 AM EDT - 3 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Jun 2, 2025, 6:00 AM EDT - 4 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

atai Life Sciences to Participate in Upcoming Investor Conferences

May 29, 2025, 8:30 AM EDT - 4 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 20, 2025, 7:00 AM EDT - 4 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 14, 2025, 7:00 AM EDT - 5 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

May 13, 2025, 7:01 AM EDT - 5 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Mar 11, 2025, 7:00 AM EDT - 7 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 27, 2025, 12:45 PM EST - 7 months ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:10 PM EST - 8 months ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Feb 20, 2025, 7:00 AM EST - 8 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Feb 12, 2025, 10:47 PM EST - 8 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

Feb 12, 2025, 4:01 PM EST - 8 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 29, 2025, 11:57 AM EST - 8 months ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Jan 10, 2025, 7:00 AM EST - 9 months ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Psychedelic Stock Deep Dive: Atai Life Sciences

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS CYBN MNMD

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 28, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 27, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Mar 4, 2024, 8:00 AM EST - 1 year ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Feb 6, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Jan 4, 2024, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

Nov 29, 2023, 6:55 PM EST - 2 years ago

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Nov 14, 2023, 7:03 AM EST - 2 years ago

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 6, 2023, 4:05 PM EDT - 2 years ago

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Oct 2, 2023, 4:13 PM EDT - 2 years ago

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

DriuxP
DriuxP Oct. 7 at 5:10 AM
$ATAI
1 · Reply
woodhous
woodhous Oct. 7 at 4:42 AM
$ATAI uupppp
0 · Reply
twiggs462
twiggs462 Oct. 7 at 3:16 AM
$ATAI "[ATAI] 20-30B Company in the next years" - Christian Angermayer
0 · Reply
sirdudeness
sirdudeness Oct. 7 at 2:43 AM
$ATAI Pardon me if someone has already posted this. https://studyfinds.org/single-psilocybin-dose-reverses-pain-depression/
0 · Reply
McGuireTO
McGuireTO Oct. 7 at 1:59 AM
$ATAI $MNMD $CMPS $PSIL Sorry it's been so long since my last update, as explained in this video - Travel in the Caribbean, Stomach flu, and surgery on my nose kept me unable to record an update. But here it is, detailing what we're looking for into tomorrow and the rest of the week!
1 · Reply
Tifosi007
Tifosi007 Oct. 7 at 1:23 AM
$ATAI Cathie’s confidence keeps building
1 · Reply
McGuireTO
McGuireTO Oct. 7 at 1:13 AM
$ATAI $MNMD $CMPS $PSIL Click here to watch the free video! Where do we stand in the psychedelic sector now that ATAI's BPL-009 Phase 3a readout broke out to higher highs, and CMPS and MNMD finally broke through their resistances? Are we anticipating continuation? What about CYBN? I cover it all in this video. I post regular technical analysis of the psychedelic sector, be sure to Like this post and follow me to stay on top of things and not miss an update! https://www.tradingview.com/chart/CYBN/XInp84lQ-Psychedelic-Sector-Update-Oct-6th/
1 · Reply
gemini112
gemini112 Oct. 7 at 12:37 AM
$ATAI Is this first time cathie wood buy this stock?
1 · Reply
UncleRoman09
UncleRoman09 Oct. 6 at 9:23 PM
$ATAI nation! Hedged of a large portion to average up on Datavault (DVLT) highly recommend at least taking a look
0 · Reply
ArsenalFC23
ArsenalFC23 Oct. 6 at 7:21 PM
$ATAI sold my complete position today for a 20% loss. Not too bad considering I was down 80% one year ago. My strategy shift away from pre revenue Bios is now almost complete. Only two I'm still holding are $SLS and $VTGN.
4 · Reply
stoxx0007
stoxx0007 Oct. 6 at 6:46 PM
$ATAI = PASS IT ON.... There is no better play than ATAI in the entire Psychedelic / Biotech sector!! 💯
0 · Reply
matrixtrade123
matrixtrade123 Oct. 6 at 6:37 PM
$ATAI __ anyone else think this could close the year $8+ __ this is what I am thinking !
3 · Reply
DriuxP
DriuxP Oct. 6 at 5:45 PM
$ATAI I sold 10% this morning (just felt I was in too heavily, must be responsible), so today will be green. You're welcome!
1 · Reply
PsychedStocks
PsychedStocks Oct. 6 at 3:44 PM
$CYBN $CMPS $MNMD $ATAI $PFE
0 · Reply
Joco8380
Joco8380 Oct. 6 at 2:53 PM
$NRXP 1) NRx Pharmaceuticals’ recent FDA Fast Track designation for NRX-100 marks a major milestone that could accelerate the path to commercialization. 2) The company’s focus on innovative treatments for depression and suicidal ideation positions it as a potential leader in a critical and underserved market. 3) With growing regulatory momentum and strong clinical progress, NRXP appears well-placed to capture investor attention and long-term value. 4) Strategic partnerships and expanding clinical data could significantly enhance NRXP’s market credibility and growth prospects. 5) As mental health therapeutics gain global importance, NRx’s advanced drug pipeline represents a high-impact investment opportunity. 6) Positive FDA engagement and clinical advancements underscore NRXP’s potential for near-term catalysts and long-term growth. $ATAI $ICU $HUMA $GHRS
1 · Reply
twiggs462
twiggs462 Oct. 6 at 2:19 PM
$ATAI Why This Billionaire is All In on Crypto, AI & Psychedelics | Christian Angermayer https://www.youtube.com/watch?app=desktop&v=_dsfD5C3M3o&list=PL3uEtSdPx8imH-VBi-LiGq7qH5_3Oofmo&index=1&t=12s
3 · Reply
Ranu5
Ranu5 Oct. 5 at 3:14 PM
$ATAI cmp 5.23 it made big base and waiting for bo so keep an eye expected level 11.39( as per base made) SL is mandatory disclaimer no buy sell recommendation
0 · Reply
twiggs462
twiggs462 Oct. 4 at 10:48 PM
$MNMD $ATAI
1 · Reply
PsychedStocks
PsychedStocks Oct. 4 at 3:34 PM
$CYBN $CMPS $ATAI $MNMD
1 · Reply
Maldof
Maldof Oct. 4 at 8:52 AM
$ATAI great interview from atais CSO https://youtu.be/uaLqRfB-ROw?si=dwxsqrZA6uuuwry1
0 · Reply
twiggs462
twiggs462 Oct. 4 at 2:26 AM
$ATAI $MNMD - James Fadiman and Jordan Gruber: Psychedelics Legalization Will Continue No Matter Who Is President - https://reason.com/podcast/2025/03/26/james-fadiman-and-jordan-gruber-psychedelics-legalization-will-continue-no-matter-who-is-president/
0 · Reply
ScottySalmon
ScottySalmon Oct. 3 at 10:41 PM
$ATAI markets are insane at the moment with crocks of s**t more than doubling SP in last 6 months. If ATAI delivers trial and FDA news in next few weeks, this fomo market will result in ATAIs SP literally exploding. If any news comes much later when this absurd market is over, then any increases will be muted.
2 · Reply